Stockscreener 앱 받기
1.38
0.72%
-0.01
시간 외 거래:
1.38
In 8 Bio Inc 주식(INAB)의 최신 뉴스
BioRestorative Therapies (NASDAQ: BRTX) adds $1M revolver and installs lender-backed directors - Stock Titan
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Palisade Bio (PALI) raises authorized shares to 450M and refreshes equity plans - Stock Titan
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
TELA Bio (NASDAQ: TELA) OKs 3.5M-share incentive plan boost - Stock Titan
Climb Bio reports encouraging Phase 1b ITP data; 250 mg cohort shows durable platelet gains - TradingView
Climb Bio (CLYM) details early budoprutug Phase 1b/2a ITP results and risks - Stock Titan
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
[8-K] Bio Green Med Solution, Inc. Reports Material Event - Stock Titan
[Form 4] KYNTRA BIO, INC. Insider Trading Activity - Stock Titan
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
Climb Bio (CLYM) director receives stock options on 40,000 common shares - Stock Titan
Climb Bio (NASDAQ: CLYM) expands equity plan evergreen to cover pre-funded warrants - Stock Titan
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform - Business Wire
Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Climb Bio, Inc. Files Form 8-K with SEC – Corporate Information, Stock Details, and Emerging Growth Status - Minichart
Climb Bio (NASDAQ: CLYM) advances CLYM116 toward Phase 2 IgAN trial - Stock Titan
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Valion Bio (NASDAQ: VBIO) investors approve major equity plan boost and share issuances - Stock Titan
Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan
New MRI biomarker backs INmune Bio (NASDAQ: INMB) Alzheimer’s drug - Stock Titan
Gossamer Bio (NASDAQ: GOSS) extends early tender deadline in major convertible note exchange - Stock Titan
Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart
Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay - Stock Titan
Passage Bio (NASDAQ: PASG) ends Gemma deal, pays $2.3M to exit lease - Stock Titan
Q32 Bio (NASDAQ: QTTB) prices $55M stock and pre-funded warrant sale - Stock Titan
Bio-Path (OTC: BPTH) unveils crypto treasury plan and $57.9M judgment tie - Stock Titan
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Korro Bio (NASDAQ: KRRO) unveils KRRO-111 AATD RNA editing data - Stock Titan
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options - Stock Titan
Debt exchange and FDA path shape Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Pharma-Bio Serv, Inc. Files Form 8-K Disclosing Submission of Matters to a Vote of Security Holders – May 2026 - Minichart
KALA BIO (KALA) files 13G/A: Baker Bros. reports 2,312 shares post-split - Stock Titan
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
Instil Bio, Inc. Reports First Quarter 2026 Financial Results – 8-K Filing Details and Key Highlights - Minichart
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027 - Stock Titan
[SCHEDULE 13G/A] PALISADE BIO, INC. Amended Passive Investment Disclosure - Stock Titan
Gossamer Bio, Inc.Common Stock (NQ: GOSS - FinancialContent
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
IPF Phase 2a results and cash runway update for GRI Bio (NASDAQ: GRI) - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan
Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
TELA Bio (NASDAQ: TELA) Q1 2026 revenue rises 3% to $19.1M - Stock Titan
TELA Bio rolls out fully resorbable hernia repair after $19M Q1 - Stock Titan
Kyntra Bio (NASDAQ: FGEN) Q1 2026 results, oncology pipeline and cash runway - Stock Titan
INmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call Transcript - Insider Monkey
Avai Bio (NASDAQ: AVAI) and Ainnova mutually end AI healthcare joint venture - Stock Titan
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
1.27%
1.43%
자본화:
|
볼륨(24시간):